Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:39:58 2024-04-24 am EDT			5-day change	1st Jan Change
112.3 ^EUR	+0.81%		+4.37%	+4.08%

Apr. 24	IPSEN : Better-than-expected Q1; guidance unchanged
Apr. 24	Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024

Ipsen: Disclosure of Transactions in Own Shares Between 06/07/2020 And 10/07/2020

July 13, 2020 at 12:01 pm EDT

Regulatory News:

Aggregated presentation by day and market

Issuer name	Issuer identification code	Transaction date	Identification code of the financial instrument	Daily total volume (in number of shares)	Daily weighted average price of shares acquired	Platform
IPSEN	549300M6SGDPB4Z94P11	7/6/2020	FR0010259150	1 693	76.7982	XPAR
IPSEN	549300M6SGDPB4Z94P11	7/7/2020	FR0010259150	0	-	XPAR
IPSEN	549300M6SGDPB4Z94P11	7/8/2020	FR0010259150	6 021	76.1183	XPAR
IPSEN	549300M6SGDPB4Z94P11	7/8/2020	FR0010259150	422	76.7758	CHIX
IPSEN	549300M6SGDPB4Z94P11	7/8/2020	FR0010259150	380	76.7133	BATE
IPSEN	549300M6SGDPB4Z94P11	7/8/2020	FR0010259150	290	76.7207	TRQX
IPSEN	549300M6SGDPB4Z94P11	7/9/2020	FR0010259150	3 356	77.921	XPAR
IPSEN	549300M6SGDPB4Z94P11	7/10/2020	FR0010259150	2 827	79.3614	XPAR
			Total	14 989	77.2556

The information detailed by transaction and the buy-back objectives are available on the company's website at the following address: http://www.ipsen.com/investors/regulated-information/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005305/en/

Latest news about Ipsen

IPSEN : Better-than-expected Q1; guidance unchanged	Apr. 24
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	Apr. 24
Ipsen: sales up 11% in Q1	Apr. 24	CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults	Feb. 13	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Transcript : Ipsen S.A., 2023 Earnings Call, Feb 08, 2024	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF
Transcript : Ipsen S.A., 2023 Pre Recorded Earnings Call, Feb 08, 2024	Feb. 07
Ipsen presents positive data for Cabometyx	Jan. 23	CF

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

112.3 EUR

Average target price

124.6 EUR

Spread / Average Target

+10.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+4.08%	9.85B
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Ipsen: Disclosure of Transactions in Own Shares Between 06/07/2020 And 10/07/2020

Latest news about Ipsen

Chart Ipsen

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Ipsen

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals